Sign up Australia
Proactive Investors - Run By Investors For Investors

Actinogen Limited readies to reveal clinical data

Actinogen Limited readies to reveal clinical data

Actinogen Limited (ASX:ACW) has been granted a trading halt by the ASX pending the results of the CSF clinical data.

The company is focussed on the treatment of Alzheimer’s disease and mild cognitive impairment.

The halt will remain in place until the opening of trade on Wednesday 30th September 2015, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full ACW profile View Profile

Actinogen Medical Ltd Timeline

Newswire
December 30 2016

Related Articles

picture of doctors
July 11 2017
The focus has switched to new, higher value “finished device products”,
Novogen: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Dr James Garner talked clinical-stage programs with investors.
picture of doctor
September 06 2017
A Phase I clinical trial is to start later this year for the LOXL-2 inhibitor

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use